- Investing.com
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Sleep Apnea Breakthrough | LivaNova's OSPREY trial reveals promising results for its Obstructive Sleep Apnea platform, potentially tapping into a large market by 2026 |
Depression Treatment Dilemma | Mixed results from the RECOVER trial for VNS Therapy in depression treatment prompt strategic reassessment, with future plans eagerly anticipated |
Financial Health Check | LivaNova maintains a strong financial position with revenue growth of 11% over 12 months and an "GREAT" financial health score from InvestingPro |
Market Valuation Insights | With a market cap of $2.88 billion and an analyst price target of $61.00, LivaNova's stock shows potential upside amid evolving growth strategies |
Metrics to compare | LIVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLIVNPeersSector | |
---|---|---|---|---|
P/E Ratio | −10.3x | 21.5x | −0.4x | |
PEG Ratio | 0.02 | 0.12 | 0.00 | |
Price/Book | 2.2x | 2.9x | 2.6x | |
Price / LTM Sales | 1.8x | 4.8x | 2.9x | |
Upside (Analyst Target) | 43.3% | 56.3% | 51.7% | |
Fair Value Upside | Unlock | 5.5% | 9.5% | Unlock |